Capricor Therapeutics (NASDAQ:CAPR) Cut to Hold at Maxim Group

Maxim Group downgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a buy rating to a hold rating in a research note released on Thursday morning, Marketbeat Ratings reports.

Several other equities research analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Piper Sandler lowered shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 price target on the stock. in a report on Thursday. HC Wainwright restated a “neutral” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Cantor Fitzgerald downgraded shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.50 price objective for the company. in a report on Thursday. Finally, LADENBURG THALM/SH SH downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday. Ten analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics currently has an average rating of “Reduce” and an average target price of $29.15.

Capricor Therapeutics Trading Down 8.1%

Shares of CAPR opened at $3.85 on Thursday. Capricor Therapeutics has a 12-month low of $2.96 and a 12-month high of $40.37. The company has a market cap of $222.95 million, a PE ratio of -1.66 and a beta of 0.42. The stock has a 50-day moving average price of $23.00 and a 200-day moving average price of $26.77.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, analysts predict that Capricor Therapeutics will post -1.62 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer owned 11,223 shares in the company, valued at $340,954.74. The trade was a 68.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 25,000 shares of company stock worth $759,158. Company insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV purchased a new position in shares of Capricor Therapeutics during the first quarter worth approximately $44,000. ACT Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $43,000. Allworth Financial LP lifted its holdings in shares of Capricor Therapeutics by 5,021.5% in the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 3,264 shares during the last quarter. State of Wyoming boosted its stake in shares of Capricor Therapeutics by 76.0% in the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,913 shares in the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 557 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

More Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Neutral Sentiment: The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 that available evidence did not support Deramiocel’s effectiveness. The vote is non-binding, so the FDA could still reach a different decision, but it is a significant setback for Capricor’s regulatory path. Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
• Neutral Sentiment: FDA briefing materials and media reports questioned whether Deramiocel met its pre-specified cardiac endpoint and challenged Capricor’s interpretation of Phase 3 results. The dispute centers on changes to the statistical analysis plan that allegedly were not agreed to by the FDA before the company resubmitted its biologics license application. Capricor plummets after FDA panel votes against Duchenne heart disease therapy
• Negative Sentiment: Multiple law firms have announced securities-fraud investigations or filed shareholder class actions alleging that Capricor made materially misleading statements or failed to disclose regulatory and clinical-data risks related to Deramiocel. The lawsuits add legal, financial and reputational risk, although the allegations have not been proven. Investors have been encouraged to contact the firms, with some notices citing a September 28, 2026 deadline. CAPR Investor Alert: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics Investors
• Negative Sentiment: Analysts responded by cutting ratings, including downgrades from Cantor Fitzgerald, Maxim Group, Ladenburg Thalmann and Alliance Global Partners. Cantor moved to Neutral with a $3.50 price target, while JonesTrading reaffirmed a Hold rating. Capricor Therapeutics downgraded by Cantor Fitzgerald

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.